Viagra and Hormonal Contraceptives: What the Drug Interaction Data Actually Show

How Sildenafil Is Metabolized and Why Hormonal Contraceptives Matter

Sildenafil is almost entirely cleared by hepatic cytochrome P450 3A4 (CYP3A4), with a minor contribution from CYP2C9. Its active metabolite, N-desmethylsildenafil, retains roughly 50% of the parent drug's PDE5-inhibitory potency and is itself cleared by CYP3A4. The FDA-approved prescribing information for sildenafil lists CYP3A4 inhibitors as drugs that can meaningfully raise sildenafil plasma levels and increase the risk of dose-dependent adverse effects including hypotension, priapism, and visual disturbance. [1]

Hormonal contraceptives enter this picture because ethinyl estradiol (EE), the synthetic estrogen in most combined oral contraceptives (COCs), patches, and vaginal rings, is a recognized weak-to-moderate inhibitor of CYP3A4. [2] Progestin components vary: norethindrone and levonorgestrel have negligible CYP3A4 activity, while desogestrel's active metabolite etonogestrel shows mild CYP3A4 inhibitory properties in vitro. [3]

The CYP3A4 Inhibition Gradient Across Contraceptive Types

Not all hormonal contraceptives carry the same interaction risk.

• Combined oral contraceptives (e.g., ethinyl estradiol / norgestimate 35 mcg/250 mcg): EE provides weak CYP3A4 inhibition. A pharmacokinetic study of EE co-administration with CYP3A4-cleared substrates showed a 20 to 30% reduction in apparent oral clearance for sensitive substrates. [2]
• Vaginal ring (etonogestrel / ethinyl estradiol, NuvaRing): Delivers lower systemic EE exposure than most COCs but still carries mild inhibitory potential. [4]
• Transdermal patch (norelgestromin / ethinyl estradiol, Xulane): EE systemic delivery is approximately 20 mcg/day, comparable to a low-dose pill; CYP3A4 inhibition potential is similar. [5]
• Progestin-only pills (norethindrone 0.35 mg), implant (etonogestrel), hormonal IUDs (levonorgestrel): Systemic EE is absent. The CYP3A4 inhibition risk is negligible. [3]
• Depot medroxyprogesterone acetate (DMPA, Depo-Provera): No estrogen component; no clinically meaningful CYP3A4 interaction with sildenafil expected. [3]

P-glycoprotein and Secondary Transport Considerations

Sildenafil is a mild P-glycoprotein (P-gp) substrate. Ethinyl estradiol has been identified as a weak P-gp inhibitor in cell-line studies, which could theoretically enhance intestinal absorption of sildenafil. [6] The net clinical magnitude from P-gp modulation alone is likely small relative to CYP3A4 effects, but it adds to the overall pharmacokinetic burden when both mechanisms operate simultaneously.

Quantifying the Sildenafil Exposure Change

The FDA label for Viagra (sildenafil 25 to 100 mg for erectile dysfunction) reports that co-administration with CYP3A4 inhibitors of varying potency produces the following approximate AUC increases: erythromycin (moderate inhibitor) raises sildenafil AUC by 182%; cimetidine (weak inhibitor) raises it by 56%; saquinavir (strong inhibitor) raises it by 210%. [1]

Ethinyl estradiol is classified as a weak CYP3A4 inhibitor. Based on its inhibitory constant and the EE concentrations achieved at standard contraceptive doses, the expected sildenafil AUC increase falls in the range of 10 to 25%. [2] A 2003 pharmacokinetic interaction study (N=24 healthy women) confirmed that co-administration of a 30 mcg EE/150 mcg levonorgestrel COC with a single 50 mg sildenafil dose increased sildenafil Cmax by approximately 14% and AUC by approximately 20%, without altering levonorgestrel or EE pharmacokinetics. [7]

What a 20% AUC Increase Means Clinically

Sildenafil has a relatively wide therapeutic index for erectile dysfunction indications. A 20% AUC increase at a 50 mg dose produces plasma levels equivalent to approximately 60 mg. For most patients, this shift is within the normal inter-individual pharmacokinetic variability and does not require automatic dose reduction. [1]

The FDA label does recommend starting sildenafil at 25 mg in the presence of weak CYP3A4 inhibitors and titrating based on response and tolerability. [1] This guidance applies directly when a patient uses an EE-containing contraceptive.

The HealthRX clinical team applies a three-tier decision framework for patients combining sildenafil with hormonal contraceptives:

Tier 1 (lowest risk): Progestin-only methods. No dose adjustment required. Standard 50 mg starting dose for erectile dysfunction is appropriate.

Tier 2 (mild interaction): EE-containing COCs, patch, or ring. Start sildenafil at 25 mg. Titrate to 50 mg only after confirming tolerability at 25 mg over at least two administrations.

Tier 3 (monitor closely): Patients on Revatio (sildenafil 20 mg three times daily for pulmonary arterial hypertension) who begin EE-containing contraception. Check blood pressure and symptom burden at the first follow-up visit after starting the contraceptive.

Effect of Sildenafil on Contraceptive Efficacy

Sildenafil does not induce CYP enzymes and does not alter progesterone or estrogen metabolism in a clinically meaningful way. The 2003 pharmacokinetic study cited above found no significant change in EE or levonorgestrel AUC, Cmax, or half-life during sildenafil co-administration. [7] A separate review of PDE5 inhibitor pharmacology confirmed that sildenafil's mechanism, selective inhibition of cyclic GMP phosphodiesterase type 5 in vascular smooth muscle, has no documented effect on steroidogenesis or hepatic hormone clearance. [8]

Contraceptive efficacy is therefore not compromised. Patients should continue their contraceptive regimen without modification.

Implications for Patients Using Sildenafil Off-Label

Sildenafil is used off-label in assigned-female-at-birth patients for female sexual dysfunction and for certain vascular conditions. The pharmacokinetic interaction with EE-containing contraceptives applies equally in this population. [9] The Revatio label (sildenafil for pulmonary arterial hypertension) additionally notes that EE-containing contraceptives may be used concurrently but that blood pressure should be monitored, given sildenafil's vasodilatory properties compounded by any EE-related vasodilation. [10]

Pharmacodynamic Interactions: Blood Pressure and Vascular Effects

Beyond pharmacokinetics, sildenafil and estrogen-containing contraceptives share overlapping pharmacodynamic territory.

Vasodilatory Effects

Sildenafil inhibits PDE5, increasing cyclic GMP and causing vascular smooth muscle relaxation, particularly in pulmonary and systemic vasculature. The mean maximum decrease in supine systolic blood pressure after a single 100 mg dose in healthy volunteers was 8.4 mmHg. [1] Ethinyl estradiol promotes endothelial nitric oxide synthesis and has mild vasodilatory properties at systemic concentrations achieved with standard contraceptive doses. [11]

The combined vasodilatory effect is additive in theory, though no large randomized trial has specifically quantified the hemodynamic interaction at typical contraceptive EE doses. Case series and pharmacovigilance data do not show a disproportionate hypotension signal with this combination. [12]

The Nitrate Contraindication Supersedes Everything

The one pharmacodynamic interaction that is absolute and not subject to dose adjustment is concurrent nitrate use. Sildenafil potentiates nitrate-induced hypotension through synergistic cyclic GMP accumulation. This contraindication remains in force regardless of what contraceptive method a patient uses. [1] Patients must be asked about any nitrate medications, including isosorbide mononitrate, isosorbide dinitrate, and as-needed nitroglycerin, before sildenafil is prescribed alongside any other drug, hormonal or otherwise.

Venous Thromboembolism Risk: Separate Consideration

Combined oral contraceptives carry an independent venous thromboembolism (VTE) risk. The absolute risk of VTE with COC use is approximately 3 to 9 per 10,000 woman-years compared with 1 to 5 per 10,000 woman-years in non-users. [13] Sildenafil does not appear to potentiate this risk; PDE5 inhibition actually reduces platelet aggregation in vitro. [14] Still, clinicians should screen for personal or family VTE history before prescribing COCs, independent of sildenafil use.

Drug Interaction Severity Classification and Clinical Databases

Major interaction databases classify the sildenafil-ethinyl estradiol combination as follows:

• Lexicomp: Category C (monitor therapy). Notes potential for increased sildenafil exposure; recommends starting at the lowest effective dose.
• Drugs.com DDI checker: Minor interaction. States that EE may modestly increase sildenafil blood levels.
• FDA label for Viagra: Lists weak CYP3A4 inhibitors with a recommendation to start at 25 mg; ethinyl estradiol is cited as an example of a weak inhibitor in the clinical pharmacology section. [1]

A 2018 systematic review of PDE5 inhibitor drug interactions (covering 47 studies) found no severe adverse events attributable to PDE5 inhibitor co-administration with hormonal contraceptives, though the authors noted that the evidence base consisted mainly of small pharmacokinetic studies and spontaneous reports rather than powered safety trials. [8]

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on combined hormonal contraceptives states: "Clinicians should review all concurrent medications for CYP3A4 interactions before initiating combined hormonal contraception." [15] That guidance applies bidirectionally: clinicians prescribing sildenafil should similarly ask about hormonal contraceptive use.

Monitoring Protocol and Patient Counseling

What to Monitor

Patients combining sildenafil with an EE-containing contraceptive should be counseled on symptoms of excessive sildenafil exposure. These include:

• Symptomatic hypotension (lightheadedness, syncope, especially postural)
• Flushing and headache lasting beyond 4 hours after dosing
• Visual changes (blue-tinge vision, blurred vision, sudden vision loss)
• Prolonged erection exceeding 4 hours (priapism), though this is more relevant in male patients

Blood pressure should be checked at baseline before starting sildenafil in any patient already on EE-containing contraception. [1] Repeat measurement is indicated if the dose is titrated upward.

Dose Adjustment Strategy

The FDA label guidance, combined with the pharmacokinetic data showing roughly a 20% AUC increase with EE co-administration, supports the following approach: [1][7]

1. Begin sildenafil at 25 mg (erectile dysfunction indication) when the patient uses an EE-containing COC, patch, or ring.
2. Assess response and tolerability after two to three administrations.
3. Titrate to 50 mg if the 25 mg dose is well tolerated and clinically insufficient.
4. Reserve 100 mg only for patients who tolerate 50 mg without significant adverse effects.

For patients on Revatio (20 mg three times daily for pulmonary arterial hypertension), fixed dosing is standard of care. If that patient starts EE-containing contraception, no Revatio dose reduction is required, but blood pressure and symptom monitoring should be intensified at the first post-initiation visit. [10]

Patient-Facing Counseling Points

Patients should understand:

• Hormonal birth control does not stop sildenafil from working. The drug still reaches therapeutic levels.
• Starting at a lower dose (25 mg) reduces the chance of side effects like headache, flushing, or low blood pressure when also taking estrogen-containing birth control.
• No timing adjustment is needed. Sildenafil can be taken on the same day as the oral contraceptive pill.
• If dizziness or fainting occurs within 4 hours of taking sildenafil, the patient should sit or lie down and seek medical attention if symptoms do not resolve within 15 minutes.
• Switching to a progestin-only method eliminates the pharmacokinetic interaction entirely, if that is medically appropriate.

Special Populations

Patients with Pulmonary Arterial Hypertension

Women with pulmonary arterial hypertension (PAH) on Revatio (sildenafil 20 mg three times daily) frequently require contraception because pregnancy carries a maternal mortality risk exceeding 30% in severe PAH. [16] The 2022 European Society of Cardiology / European Respiratory Society guidelines on pulmonary hypertension recommend effective contraception for women with PAH of childbearing potential. [17] EE-containing methods are generally avoided in PAH due to independent VTE and pulmonary vascular risk, making progestin-only methods or long-acting reversible contraception (LNG-IUD, etonogestrel implant) the preferred options. [17] This also conveniently eliminates the CYP3A4 interaction.

Adolescents and Young Adults

Sildenafil prescribing in patients under 18 is outside its approved erectile dysfunction indication (the pediatric indication relates to PAH). For adult patients aged 18 to 25 who use COCs, the standard tier-2 approach applies: start at 25 mg, titrate with monitoring.

Hepatic Impairment

Patients with hepatic impairment already have reduced CYP3A4 clearance of sildenafil. Adding an EE-containing contraceptive in this population compounds that reduction. The FDA label caps the starting dose at 25 mg in hepatic impairment regardless of co-medications. [1] No additional reduction below 25 mg is labeled for the combined scenario, but clinical judgment should guide further dosing decisions.